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AtherosclerosisThe renin-angiotensin-aldosterone system (RAAS) regulates
inﬂammation and vascular remodeling thus playing an important
role in atherosclerosis, kidney disease and heart failure. As an
example of this, the effector hormone Angiotensin II (AngII) was
shown to promote oxidative stress, endothelial dysfunction and
vascular inﬂammation [1], all of which would be detrimental.
However, inhibiting the RAAS now goes beyond blood pressure
reduction and is an important component of the baseline treatment
of heart failure, cardiorenal syndrome and diabetic nephropathy. As
an example of its protective role in atherosclerosis, the HOPE (Heart
Outcomes Prevention Evaluation) trial showed a 37% risk reduction
in cardiovascular death by Ramipril in people with diabetes [2].
Angiotensin receptor blockers (ARBs) and angiotensin-
converting enzyme inhibitors (ACEIs) reduce effectively the pro-
duction of AngII, but consequently increase plasma renin concen-
tration because of the loss of negative feedback by AngII on renin.
On one hand this might lead to a limited blockade of the RAAS, on
the other it could lead to activation of possible alternative pathways
by renin [3]. This issue raised the demand for different RAAS in-
hibitors. In 2007 the US Food and Drug Administration ﬁrst
approved Aliskiren. This orally active drug acts a direct renin
antagonist, thereby antagonizing the rate-limiting step of the RAAS
without raising the plasma renin activity. Plasma renin activity hasDOI of original article: http://dx.doi.org/10.1016/j.atherosclerosis.2014.10.098.
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events [4], so the pre-conditions for Aliskiren seemed to be
promising. However to date, Aliskiren has failed to prove itself in
cardiovascular outcome studies. The ALTITUDE (Aliskiren Trial in
Type 2 Diabetes Using Cardio-renal Disease Endpoints) study was
terminated prematurely due to the concerns of higher stroke risk
and apparently no beneﬁcial effects of Aliskiren. However, in
experimental setups, Aliskiren was shown to be protective and
reduced early atherosclerotic lesions [5].
In this issue of AtherosclerosisWu and colleagues [6] investigate
the effect of RAAS inhibition by Aliskiren on neovessel formation
and atherosclerotic plaque development in an apolipoprotein E-
deﬁcient (ApoE /) mouse model of late atherosclerosis. The key
feature of this study is a roughly 54% reduction of intima/media
ratio as indicator of plaque size as well as a signiﬁcant reduction of
neovascularization in aortic roots of Aliskiren-treated mice in a
blood pressure-independent matter. The physiological process of
new vessel formation restores normoxia in the vessel wall, whereas
pathologically increased neovascularization leads to the vicious
cycle of disease progression by inﬂammation, wall thickening and
hypoxia [7]. Wu et al. [6] further found an increased collagen and
elastin plaque content indicating a more stable plaque, while
macrophage inﬁltration, the expression of cathepsin S protein
(CatS) and toll-like receptor (TLR) 2 were reduced. TLR play an
important role in the innate immune system and several lines of
evidence indicate an association with atherosclerosis [8]. CatS is an
excreted lysosomal protease which is linked to extracellular matrix
degradation such as elastin and collagen and therefor potentially
responsible for plaque destabilization [9].
To further evaluate the effect of CatS on atherosclerosis, the
authors went on and generated ApoE/ CatS/ mice. CatS-
lacking mice showed signiﬁcantly less plaques, which strengthens
the potential role of CatS on atherogenesis, and particularly on
plaque destabilization. However, additionally, the authors demon-
strated that treatment with Aliskiren did not have further effects on
plaque reduction in ApoE/ CatS/mice indicating CatS being a
downstream target of the RAAS. As would be expected, Aliskiren
treatment reduced serum AngII. In human umbilical vein endo-
thelial cells (HUVECs) Wu et al. demonstrated that CatS expression
was induced by AngII, whereas RAAS inhibition as well as siRNAr the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ﬁnding supports a potential pathway of CatS being a downstream
target of AngII via a TLR2-mediated cascade.
Overall this study advances our understanding of the RAAS in
the context of atherosclerosis and vascular remodeling. Particularly
the link between Angiotensin, TLR2 and CatS is interesting and
promises future interventional targets. However, several issues
remain still unclear. In an earlier publication the same group had
already demonstrated that RAAS inhibition via AngII type 1 re-
ceptor blockade by Olmesartan resulted in reduction of plaque size
in ApoE/ mice as well as reduced CatS tissue levels [10]. These
ﬁndings make clear that the effect of Aliskiren in this study is most
likely due to the inhibition of RAAS, but possible effects of Aliskiren
other than reduction of AngII remain to be elucidated.
Interestingly, Wu et al. [6] showed a reduction of (pro) renin
receptor (PRR) in plaques of Aliskiren-treated mice. The PRR has
recently been discoveredwith its intracellular downstream cascade
and is particularly expressed in vascular smooth muscle cells of
heart and kidney [3]. Therefore PRR might play a potential role in
atherosclerosis. PRR can be activated by prorenin and also by renin
itself. ARBs and ACEIs increase, whereas Aliskiren reduces plasma
renin activity, so effects on the PRR -and therefore possibly on
atherosclerosis- might be contrary, but remain to be elucidated.
Another aspect that requires further investigation is whether
Aliskiren acts also at the tissue level. In fact, recently there has been
some evidence that Aliskiren inhibits tissue RAAS more efﬁciently
due to direct antagonism of the non-proteolitically activated pro-
renin [3]. Wu and colleagues [6] have only focused on local effects
of RAAS, but discrimination between the tissue-speciﬁc and the
systemic effects of Aliskiren need further evaluation and could help
explain the results of clinical outcome studies. Interestingly, in a
different study using a model of metabolic syndrome, mice lacking
renin expressed a favorable phenotype due to higher energy
expenditure and resistance to diet-induced obesity [11]. In the
current study a different mouse model has been used, but at least
with a similar setup also using a high fat diet on mice with a C57BL/
6 genetic background. Wu et al. did not notice an effect of Aliskiren
as direct renin antagonist on weight gain, however the energy
expenditure was not tested. Further experiments are needed to
reveal if Aliskiren might increase energy expenditure and would be
favorable in patients with metabolic syndrome. As a ﬁnal point, the
authors state, supported by their in vitro experiments using a PI3K
inhibitor, that the PI3K/Akt pathway might be involved in AngII
mediated CatS expression. This ﬁnding is interesting, but weakly
supported. Previous studies have showed few pathways in this
matter might be involved. Therefore more studies are eventually
needed to understand the actual cascades.
In conclusion, Aliskiren has shown promising results in an
experimental setup like this study, which also highlights the
importance of the RAAS in atherogenesis. Especially the resulting
difference of low plasma renin activity compared to treatment with
ARBs and ACEIs seems interesting, but additional investigations areneeded to distinguish between RAAS- and non-RAAS-related ef-
fects of those substances. In the ALTITUDE trial Aliskiren combined
with an ACEI failed to prevent cardiovascular outcomes in patients
with Type 2 Diabetes, showing possible harmful effects. Previously,
ARBs and ACEIs in combination have failed as well [12]. It is
intriguing to hypothesize that a tissue-speciﬁc effect of Aliskiren
explains the negative performance in diabetic patients, but it may
also be a promising treatment option in speciﬁc patients inde-
pendently from ARBs and ACEIs.
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